366 related articles for article (PubMed ID: 32825618)
1. Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment.
Juan A; Cimas FJ; Bravo I; Pandiella A; Ocaña A; Alonso-Moreno C
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825618
[TBL] [Abstract][Full Text] [Related]
2. Investigational antibody-drug conjugates in clinical trials for the treatment of breast cancer.
Okines AFC; Ulrich L
Expert Opin Investig Drugs; 2021 Aug; 30(8):789-795. PubMed ID: 34114911
[No Abstract] [Full Text] [Related]
3. N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability.
Ko MJ; Song D; Kim J; Kim JY; Eom J; Sung B; Son YG; Kim YM; Lee SH; You WK; Jung J
MAbs; 2021; 13(1):1914885. PubMed ID: 33904380
[TBL] [Abstract][Full Text] [Related]
4. Nanomedicines based drug delivery systems for anti-cancer targeting and treatment.
Jain V; Jain S; Mahajan SC
Curr Drug Deliv; 2015; 12(2):177-91. PubMed ID: 25146439
[TBL] [Abstract][Full Text] [Related]
5. Advancement of nanoscience in development of conjugated drugs for enhanced disease prevention.
Taneja P; Sharma S; Sinha VB; Yadav AK
Life Sci; 2021 Mar; 268():118859. PubMed ID: 33358907
[TBL] [Abstract][Full Text] [Related]
6. Development of a novel thermal-sensitive multifunctional liposome with antibody conjugation to target EGFR-expressing tumors.
Liu KC; Arivajiagane A; Wu SJ; Tzou SC; Chen CY; Wang YM
Nanomedicine; 2019 Jan; 15(1):285-294. PubMed ID: 30391483
[TBL] [Abstract][Full Text] [Related]
7. Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates.
Kolodych S; Michel C; Delacroix S; Koniev O; Ehkirch A; Eberova J; Cianférani S; Renoux B; Krezel W; Poinot P; Muller CD; Papot S; Wagner A
Eur J Med Chem; 2017 Dec; 142():376-382. PubMed ID: 28818506
[TBL] [Abstract][Full Text] [Related]
8. Antibody conjugated nanoparticles as a novel form of antibody drug conjugate chemotherapy.
Johnston MC; Scott CJ
Drug Discov Today Technol; 2018 Dec; 30():63-69. PubMed ID: 30553522
[TBL] [Abstract][Full Text] [Related]
9. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles.
Owen SC; Patel N; Logie J; Pan G; Persson H; Moffat J; Sidhu SS; Shoichet MS
J Control Release; 2013 Dec; 172(2):395-404. PubMed ID: 23880472
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of harmful tumour-associated proteolysis by nanoparticulate system.
Kos J; Obermajer N; Doljak B; Kocbek P; Kristl J
Int J Pharm; 2009 Nov; 381(2):106-12. PubMed ID: 19422896
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer.
Bartsch R
Expert Opin Investig Drugs; 2020 Sep; 29(9):901-910. PubMed ID: 32701032
[TBL] [Abstract][Full Text] [Related]
12. Combinational drug delivery using nanocarriers for breast cancer treatments: A review.
Olov N; Bagheri-Khoulenjani S; Mirzadeh H
J Biomed Mater Res A; 2018 Aug; 106(8):2272-2283. PubMed ID: 29577607
[TBL] [Abstract][Full Text] [Related]
13. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
14. Benefits and challenges of antibody drug conjugates as novel form of chemotherapy.
Fatima SW; Khare SK
J Control Release; 2022 Jan; 341():555-565. PubMed ID: 34906604
[TBL] [Abstract][Full Text] [Related]
15. Liposomal drug delivery systems: from concept to clinical applications.
Allen TM; Cullis PR
Adv Drug Deliv Rev; 2013 Jan; 65(1):36-48. PubMed ID: 23036225
[TBL] [Abstract][Full Text] [Related]
16. Advances with antibody-drug conjugates in breast cancer treatment.
Abdus Subhan M; Torchilin VP
Eur J Pharm Biopharm; 2021 Dec; 169():241-255. PubMed ID: 34748933
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of Selenium Immunoconjugates against Triple Negative Breast Cancer Cells.
Khandelwal S; Boylan M; Spallholz JE; Gollahon L
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373175
[TBL] [Abstract][Full Text] [Related]
18. Design and In Vitro Evaluation of Bispecific Complexes and Drug Conjugates of Anticancer Peptide, LyP-1 in Human Breast Cancer.
Timur SS; Bhattarai P; Gürsoy RN; Vural İ; Khaw BA
Pharm Res; 2017 Feb; 34(2):352-364. PubMed ID: 27896591
[TBL] [Abstract][Full Text] [Related]
19. Organic Nanocarriers for Bevacizumab Delivery: An Overview of Development, Characterization and Applications.
Alves ACS; Bruinsmann FA; Guterres SS; Pohlmann AR
Molecules; 2021 Jul; 26(14):. PubMed ID: 34299401
[TBL] [Abstract][Full Text] [Related]
20. Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer.
Akbarzadeh Khiavi M; Safary A; Barar J; Ajoolabady A; Somi MH; Omidi Y
Cell Mol Life Sci; 2020 Mar; 77(6):997-1019. PubMed ID: 31563999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
